Also known as: Pardes Biosciences
We break viruses
Company went public
Event Year: 2021
Company went public
Event Year: 2021
Pardes Biosciences is dedicated to the development of orally administered antiviral medications designed for both the treatment and prevention of viral infections. Their primary focus has been on addressing the challenges posed by viruses such as COVID-19, aiming to provide accessible and effective therapeutic solutions.
Pardes Biosciences is dedicated to the development of orally administered antiviral medications designed for both the treatment and prevention of viral infections. Their primary focus has been on addressing the challenges posed by viruses such as COVID-19, aiming to provide accessible and effective therapeutic solutions.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2020
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2020
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 2
Hiring: No
Team size: 2
Hiring: No
